Estrogen Exhibits a Biphasic Effect on Prostate Tumor Growth through the Estrogen Receptor β-KLF5 Pathway
Authors:
- 1 January 2016
- journal article
- research article
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 36 (1) , 144-156
Abstract
Estrogens are effective in the treatment of prostate cancer; however, the effects of estrogens on prostate cancer are enigmatic. In this study, we demonstrated that estrogen (17β-estradiol [E2]) has biphasic effects on prostate tumor growth. A lower dose of E2 increased tumor growth in mouse xenograft models using DU145 and PC-3 human prostate cancer cells, whereas a higher dose significantly decreased tumor growth. We found that anchorage-independent apoptosis in these cells was inhibited by E2 treatment. Similarly, in vivo angiogenesis was suppressed by E2. Interestingly, these effects of E2 were abolished by knockdown of either estrogen receptor β (ERβ) or Krüppel-like zinc finger transcription factor 5 (KLF5). Ιn addition, E2 suppressed KLF5-mediated transcription through ERβ, which inhibits proapoptotic FOXO1 and proangiogenic PDGFA expression. Furthermore, we revealed that a nonagonistic ER ligand GS-1405 inhibited FOXO1 and PDGFA expression through the ERβ-KLF5 pathway and regulated prostate tumor growth without ERβ transactivation. Therefore, these results suggest that E2 biphasically modulates prostate tumor formation by regulating KLF5-dependent transcription through ERβ and provide a new strategy for designing ER modulators, which will be able to regulate prostate cancer progression with minimal adverse effects due to ER transactivation.Keywords
Funding Information
- Ministry of Education, Culture, Sports, Science, and Technology
- Japan Society for the Promotion of Science (23790075)
This publication has 61 references indexed in Scilit:
- Estrogens and Prostate Cancer: Etiology, Mediators, Prevention, and ManagementEndocrinology and Metabolism Clinics of North America, 2011
- Selective and potent agonists for estrogen receptor beta derived from molecular refinements of salicylaldoximesEuropean Journal of Medicinal Chemistry, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- A role for VEGF as a negative regulator of pericyte function and vessel maturationNature, 2008
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- New insights into the classical and non-classical actions of estrogen: Evidence from estrogen receptor knock-out and knock-in miceMolecular and Cellular Endocrinology, 2008
- FOXOs, cancer and regulation of apoptosisOncogene, 2008
- UCSF Chimera—A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004
- KLF5 is frequently deleted and down‐regulated but rarely mutated in prostate cancerThe Prostate, 2003